This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
In the phase II FIGHT trial, adding bemarituzumab to chemotherapy led to longer progression-free survival and overall survival in patients with advanced FGFR2b-positive gastric or gastroesophageal junction cancers. However, the agent was also associated with more side effects, including eye problems.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
This OnlineFirst version was published on February 11, 2021
doi: 10.1158/2159-8290.CD-NB2021-0312
FGFR Inhibitor Stymies Gastric Cancer
Jump to section
Advertisement